Product Compliance And Certification For Dietary Supplement In Japan
A “dietary supplement” name or overseas supplement certificate does not create a single Japanese product-approval route. First decide whether the exact formulation and intended presentation are food at all; then select one permissible food-claim route, and separately clear food safety, Japanese labelling, advertising and—if imported—shipment notification.
This is a product-specific cross-regime map for measured-dose vitamins, botanicals, probiotics and other concentrated preparations, not a promise of approval. A capsule shape alone does not decide the category: ingredients, medicinal-style claims, presentation and sale method matter together.
Classify the actual capsule, tablet or powder before choosing a claim
- Ingredient identity: record Latin botanical name and plant part, extract ratio/solvent, strain where relevant, chemical form, daily dose and every excipient. Check current Japanese food–drug ingredient classification and food/additive restrictions; overseas legality does not settle Japan.
- Claim wording: compare every pack, website, marketplace and influencer statement with the proposed Japanese claim. Disease treatment or prevention, medicine-like dose instructions or other medicinal positioning can trigger a pharmaceutical assessment even when the same ingredient is sold abroad as food.
- Food-claim objective: choose either no function claim, a qualifying prescribed nutrient-function statement (FNFC), a substantiated notified function claim (FFC), or an individually permitted FOSHU statement. CAA says the three health-function-food systems cannot be combined on one product.
- Presentation and users: identify capsule/tablet/powder format, intended daily consumption, expected consumers and any warning populations; do not assume a foreign “dietary supplement” category or label travels unchanged.
- Supply route: decide whether manufactured in Japan or imported for sale; identify the importing food business and the business responsible for Japanese label/FFC records. For imports for sale, the MHLW Food Sanitation Act notification applies per importation.
Japan dietary-supplement route matrix
| Route / trigger | What to do before launch | What it does not establish |
|---|---|---|
| Ordinary food — no permitted functional benefit claim | Complete food/additive safety, applicable Japanese food label, marketing checks and import notification if applicable; nutritional composition statements also require review. | Being sold as ordinary food is not an exemption from food law, and medicinal claims cannot be added. |
| FNFC — standard function of a specified nutrient | Check qualifying nutrient, prescribed daily-intake upper/lower limits, mandatory standardized statement and caution language; document compliance. No individual CAA filing for the FNFC route. | You cannot use bespoke botanical or disease claims or combine FNFC with another health-function-food route. |
| FFC — product/functional ingredient with evidence-backed function | Prepare safety, function substantiation, manufacture/quality, adverse-event system and label documentation; submit required information to CAA before sale under current rules. | A notification is not government approval of safety or effectiveness; publication or a number is not a state certification. |
| FOSHU — specifically authorised health-use statement | Seek product-by-product governmental permission with an applicable safety/efficacy package before making the approved health-use indication. | Permission and any official mark concern the specified permitted product/claim; they do not approve unrelated SKUs. |
| Potential pharmaceutical — ingredient, claim, presentation or dosage red flag | Stop food-route sign-off, obtain Japan-specific food/drug classification advice and determine whether the pharmaceutical regime applies. | Changing a label alone may not resolve an ingredient classified as exclusively medicinal. |
Three formulation/claim combinations that change the decision
| Example product / ambition | Classification question | Evidence to request before deciding |
|---|---|---|
| Concentrated botanical-extract capsule, advertised for blood-pressure treatment | Does the exact plant part/extract or the disease claim place the SKU on the pharmaceutical side of Japan’s food–drug boundary? | Full botanical identification, extract specification, daily exposure and all Japanese advertising. Hold food-route release pending classification. |
| Vitamin D tablet with the prescribed nutrient function plus a bespoke sleep claim | Does it qualify for the fixed FNFC statement, and is a separate sleep claim even eligible under a different single route? FNFC and FFC cannot be combined. | Daily vitamin amount, exact proposed claim texts, other ingredients and claim-specific substantiation. Select one route before approving artwork. |
| Probiotic powder with a digestive-function claim and a new contract manufacturer | Can the strain, viable count and intended function be supported under the selected route, and do changes affect the documented manufacturing and claim basis? | Strain identity, viable count at end of shelf life, safety/function evidence, facility/process changes and Japanese label; check FFC change rules if notified. |
Evidence pack: formulation, source and claim must match
- Locked bill of materials with quantitative per-serving and daily-dose specifications, ingredient origin, additives and batch-to-batch tolerances.
- For plant extracts: species/part, extraction and standardisation process, marker compounds, potential contaminants and supplier traceability; for probiotics: strain designation and viable-count method.
- Manufacturer process map, hygiene/HACCP controls as applicable, change control and batch records; for relevant FFC extract-based tablets/capsules, verify the specific manufacture/processing GMP provisions and inspection materials.
- Targeted test plan based on ingredient risk: identity/assay, microbiological criteria, heavy metals or other contaminants, stability/shelf life, and supporting accredited reports where appropriate; no single mandatory universal “supplement test panel” is assumed.
- Scientific substantiation precisely matched to claimed function, functional ingredient, dose, population, final formulation and chosen route; separate marketing testimonials from eligible evidence.
- Japanese artwork and claim inventory covering mandatory particulars, allergen review, nutrition information, origin/importer details as applicable, warnings, dosage and e-commerce advertising.
- For import: product/manufacture descriptions, relevant test documents and importing-party details for MHLW quarantine-station review; for FFC: current CAA submission forms and health-harm collection/reporting process.
FFC manufacturing controls and 2026 change checks
Following the red-yeast-rice incident, Japan revised its FFC framework in 2024. CAA now publishes detailed notification guidance updated 1 October 2025, 2025-system forms and specific manufacturing/processing controls for certain naturally derived extract tablets and capsules. These are route-specific obligations—not a claim that every ordinary supplement needs FFC filing or the same GMP rule.
The CAA's 2026 official overview states that the transitional period for the FFC GMP requirements and revised label presentation ended on 31 August 2026. These changes must therefore be checked against the current product and manufacturing process; they are not a universal GMP certificate requirement for all ordinary supplements. Before contracting a factory or submitting a new FFC notification, check the latest CAA guidance, establish health-harm information intake and reporting as applicable, and determine which self-inspection and reporting obligations apply. A voluntary laboratory certificate is not a substitute.
Japanese label and advertising release checklist
- Mandatory food labelling for the Japanese market must be in Japanese: localize and substantiate product identity, ingredients/additives, quantity, dates, storage, responsible party, nutrition and allergen information as applicable.
- Use only the permitted category language: FNFC prescribed nutrient wording; FFC notified statement and required notices; FOSHU specifically permitted indication. A health-function-food route is not optional decoration on a general-food claim.
- Apply an evidence-and-legality check to the product name, before/after graphics, landing pages, marketplace thumbnails and paid advertising, not only the carton.
- Prohibit unsubstantiated disease prevention/treatment and misleading governmental-endorsement language. “FDA registered”, foreign GMP or third-party seals do not establish Japanese CAA approval.
- Confirm that Japanese daily-dose directions, ingredient concentrations, warnings and advertised audience match the exact evidence and the Japanese pack; avoid automatic translation of foreign claims.
- Keep the approved artwork version and translated web copy controlled; re-review if the extract, dose, factory, claim or importing entity changes.
Four release gates for an imported or domestic supplement
| Release gate | Do not release until |
|---|---|
| Classification | No unresolved exclusively-medicinal ingredient, pharmaceutical claim, additive or food-safety classification issue. |
| Claims and file | Selected one valid food-function route and completed its specific requirements; FFC record/notification or FOSHU permission if required. |
| Physical product and pack | Representative lots, supplier/contaminant evidence and fully reviewed Japanese label/advertising are aligned. |
| Shipment and monitoring | If imported for sale: per-shipment food import notification/inspection pathway cleared; define post-sale complaints, adverse-health information handling and change escalation. |
Scope boundaries and closely related products
This page owns the combined route for concentrated dietary supplements and the final coordination between ingredient, claim, format and shipment. Broader food supplements, bulk protein powders and generic food items have separate product-specific considerations:
Official Japanese regulatory starting points
- CAA: health-function schemes and exclusivity
- CAA: nutrient-function foods
- CAA: FFC current notifications and manufacturing updates
- CAA: FOSHU individual permission
- MHLW: food import notification
- CAA: Japanese food-labelling guidance
- MHLW: food/drug classification standard
- MHLW: updated medicinal ingredient lists
- CAA: public FFC notification search
- CAA: food health-function overview
- CAA: 2026 reforms and transitional period
Dietary supplement questions for Japan
Can I sell a US- or EU-labelled supplement without Japanese approval?
An overseas status is not Japan-wide authorisation. General food may not need product-specific FFC/FOSHU permission, but Japan-specific ingredient, advertising, Japanese label and import rules still apply; a medicinal ingredient or claim can change the route.
Does a vitamin capsule automatically qualify for FNFC?
No. The nutrient must be on the prescribed list, the daily intake must meet the specified range, and the exact prescribed function statement and warnings must be used. A multivitamin or added botanical does not by itself qualify every proposed benefit.
Is an FFC notification number a safety certificate?
No. FFC involves pre-sale submission and public disclosure under the operator’s responsibility; CAA does not individually approve the evidence as it does under FOSHU. Check the current status and the declared ingredient/function in the CAA database.
Will GMP or a laboratory certificate permit a botanical-extract capsule to launch?
Not by itself. The applicable manufacturing rules depend on the route and product, including particular FFC extract-based tablets/capsules. Ingredient legality, evidence, claims, labels and shipment rules require separate sign-off.
What changes if I switch extract supplier or increase the daily dose?
Reassess food/drug status, safety/specifications, stability, claim evidence, artwork, FFC/FOSHU change obligations where relevant and import documents before shipping the changed product.